Google is rolling out a significant update to its Chrome browser, embedding advanced Gemini AI capabilities directly into the user interface. The move signals a strategic push to make AI a central, everyday tool for web navigation and tasks.
Morgan Stanley has upgraded Johnson & Johnson to 'Overweight,' raising its price target to $262, citing confidence in the healthcare giant's robust pipeline of new pharmaceuticals and medical devices.
ARK Invest's Cathie Wood has aggressively added to her position in Broadcom (AVGO) this month, signaling strong conviction in the chipmaker's AI and datacenter prospects despite recent share price weakness, as analysts also turn bullish on the stock's long-term trajectory.
With gold and silver hitting record highs amid market turbulence, numismatic experts argue that certified rare coins offer a unique blend of tangible value, historical significance, and surprising liquidity for discerning investors.
As XRP hovers around $2, a stark divide emerges between institutional and algorithmic forecasts for its 2026 value. Standard Chartered's bullish $8 target contrasts with more cautious AI projections, with the outcome likely hinging on ETF inflows, regulatory clarity, and real-world adoption.
Global commodity markets opened the new week and month deep in negative territory, with the energy sector plummeting an average of 7.3% and grains facing headwinds from shifting trade flows and seasonal pressures.
A new study highlights a persistent gap between finance and cybersecurity leaders on strategic alignment, risk measurement, and investment priorities, despite widespread recognition of cyber threats.
A couple approaching retirement with $1 million in savings and $42,000 in expected Social Security benefits questions if a $90,000 annual budget is feasible. Financial experts weigh the critical factors—from tax implications to withdrawal rates—that will determine the sustainability of their plan.
While Apis Capital's flagship fund posted stellar 2025 returns, its latest investor letter spotlights the ongoing divergence of opinion on AI pure-plays like C3.ai, where heavy investment needs clash with market expectations for profitability.
Russia's premier cryptocurrency miner, BitRiver, faces insolvency proceedings as its CEO is placed under house arrest, marking a dramatic fall for a firm already crippled by international sanctions and mounting legal disputes.
A new report highlights how small and medium-sized businesses are leveraging AI, hyper-personalization, and sustainable practices not just to adapt, but to lead in a rapidly evolving marketplace.
Despite a steep share price decline, UiPath is carving out a dominant position in the burgeoning 'agentic AI' market, which promises to automate complex workflows. Strong customer loyalty and improving profitability suggest the automation software provider may be undervalued ahead of a projected industry explosion.
Piper Sandler and Barclays have raised price targets for CytomX Therapeutics (CTMX), citing promising early-phase data for its experimental colorectal cancer therapy. Updated results from a larger patient cohort are expected this quarter.
Following the FDA's decision to remove the clinical hold on Intellia's Nex-Z hATTR-PN trial, analysts at Baird and H.C. Wainwright have significantly raised their price targets for the CRISPR gene-editing pioneer, citing reduced regulatory risk and a clearer path forward.
Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.
Goldman Sachs has downgraded MoonLake Immunotherapeutics (MLTX) to Sell, highlighting the failed VELA-2 trial endpoint and persistent approval risks for its key drug, sonelokimab, despite a competing firm's more bullish outlook.
The Apis Flagship Fund reported robust quarterly and annual gains for 2025, significantly beating global benchmarks. While highlighting its performance drivers, the fund's investor letter also discussed its position on gene therapy firm uniQure (QURE).
CFOs are no longer just funders of AI experiments but central architects of its enterprise-wide deployment, navigating a critical shift from promise to production.
Gold and silver prices tumbled from recent highs following the Fed chair nomination, prompting analysts to debate whether the sell-off marks a healthy correction or a shift in the long-term hedge narrative.
Once considered a win-win solution, transforming closed landfills into solar farms faces a complex reality of high costs, regulatory hurdles, and site-specific challenges, even as demand for clean energy and affordable power surges.
